SPRC SciSparc Ltd
Price Chart
Executive Summary
SciSparc Ltd. announced that NeuroThera Labs, in which it holds a 75% stake, has filed a patent application in Hong Kong with Clearmind Medicine for a novel MEAI-PEA combination therapy targeting major depressive disorder. The filing highlights a potential non-hallucinogenic, neuroplastogenic treatment, but no clinical data, financial terms, or commercial timelines were provided.
Actionable Insight
Monitor for future clinical updates, patent approvals, or partnership expansions; current announcement is speculative and lacks near-term commercial catalysts.
Key Facts
- SciSparc holds ~75% controlling interest in NeuroThera Labs Inc. (TSXV: NTLX).
- Patent application filed in Hong Kong by Clearmind Medicine for a combination therapy of MEAI (from Clearmind) and PEA (from NeuroThera) to treat major depressive disorder (MDD).
- No clinical trial results, revenue projections, or financial details disclosed.
- Therapy described as non-hallucinogenic and potentially safer/affordable vs. SSRIs, but remains pre-commercial and speculative.
- Forward-looking statements include risks related to development, regulatory approval, and market competition.
Financial Impact
No immediate financial impact — early-stage IP development with no disclosed funding, milestones, or revenue potential.
Risk Factors
- No guarantee the patent will be granted or provide meaningful IP protection.
- Therapy is pre-clinical — significant regulatory and development risks remain.
- SciSparc’s market cap is very small ($2M), increasing volatility and liquidity risk.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3256253 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 4, 2026
5d ago
|
6-K
| $11.54 $11.44 | ▼ −0.87% | ▲ +1.73% | $9.31 (−19.32%) |
|
Jun 4, 2026
5d ago
|
Press Release
| $11.54 $11.44 | ▼ −0.87% | ▲ +1.73% | $9.31 (−19.32%) |
|
May 29, 2026
11d ago
|
6-K
| $9.81 $10.59 | ▲ +7.95% | ▲ +7.68% | $9.31 (−5.10%) |
|
May 28, 2026
12d ago
|
Press Release
| $10.55 $9.81 | ▼ −7.01% | ▼ −7.26% | $9.31 (−11.75%) |
|
Mar 16, 2026
12w ago
|
Press Release
| $4.32 $4.62 | ▲ +6.94% | ▲ +6.67% | $9.31 (+115.51%) |
|
Mar 12, 2026
12w ago
|
Press Release
| $4.73 $4.36 | ▼ −7.82% | ▼ −7.22% | $9.31 (+96.83%) |
|
Mar 10, 2026
13w ago
|
Press Release
| $4.02 $3.85 | ▼ −4.23% | ▼ −4.12% | $9.31 (+131.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access